White Paper

Biologic Drug Products: A 5-Point Strategy For Building A Robust CMC Dossier

Source: Thermo Fisher Scientific

By Daniela Decina, Sr. Director, Regulatory Affairs, Thermo Fisher Scientific, and Michele Duggan, Sr. Manager, Regulatory Affairs, Thermo Fisher Scientific

GettyImages-1303133599-lab-computer-research-virus

Getting biological drug products to first-in-human (FIH) trials requires a deep and nuanced understanding of the scientific and regulatory challenges unique to these complex large molecule substances. Prioritizing regulatory CMC guidance and careful preparation of quality dossiers is integral to success from the very early stages throughout clinical development. This report identifies key strategies for developing a carefully executed, robust CMC dossier and avoiding common deficiencies that lead to clinical holds.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online